COMMENTARY
Colonic Mucosal Aberrant Crypt Foci: Are They Useful Intermediate Endpoints for Predicting and Understanding the Development of Colonic Mucosal Neoplasia?
Cancer of the colon is one of the leading causes of cancer-related morbidity and mortality in humans living in western developed countries. Both hereditary and environmental factors contribute to the development of colorectal neoplasia. Thus, it is important that toxicologic pathologists have an understanding of the morphologic development and biology of this disease so as to accurately identify and interpret alterations that occur in the colonic mucosa of the species in which the potential toxicity of products are characterized. The article by C. M. Fenoglio-Preiser and A. Noffsinger in this issue of Toxicologic Pathology (pp. 632-642) discusses the relationship of colonic mucosal aberrant crypt foci (ACF) in rodents and humans to the development of colonic mucosal neoplasia. Aberrant crypt foci are believed to be the earliest morphologic alteration in the colonic mucosa that occurs during the development of colonic mucosal neoplasia. The review by Fenoglio-Preiser and Noffsinger raises two important questions that relate to the practice of toxicologic pathology. First, can ACF be used as intermediate endpoints to assess a test material's ability to induce or alter the development of colonic neoplasia?
Second, how has the discovery of ACF improved our understanding of the biology of the colonic mucosa and the development of colonic neoplasia? It is important to emphasize that ACF is a term that refers to alterations in colonic crypt morphology observed by viewing the mucosal surface at low magnification. The term ACF should not be used as a histologic diagnosis (23) . Aberrant crypt foci have not been reported as spontaneous lesions in rodents, which is consistent with the rarity of colonic neoplasia in rodents. However, ACF are readily induced in rodents with the use of genotoxic carcinogens that induce colonic neoplasia. The number of ACF that develop is dependent on the dose of the carcinogen. Several compounds known to inhibit the development of colonic neoplasia in genotoxin induced rodent models also inhibit the development of ACF (20, 22) . Most notable among these are cyclooxigenase inhibitors such as aspirin and non-steroidal anti-inflammatory drugs, which have been shown to inhibit tumor development in both humans and rodents. However, there are reports that document a lack of correlation between the location of tumor development and the location of ACF (2), and a lack of correlation between the frequency of ACF and subsequent tumor formation induced by different carcinogens (21) . There are also examples of compounds that promote tumor development and inhibit the development of ACF (17, 29) . In mice, differences in strain susceptibility to tumor development does not consistently correlate with the frequency of ACF (18) . Similarly ApcMIN-mice, which have a dominant mutation of the adenomatous polyposis coli (APC) gene, spontaneously develop colonic neoplasia, but ACF are rarely observed in the mucosa (11, 19) . The development of colonic tumors induced by non-genotoxic colon carcinogens has not been studied extensively. However, one report indicates these compounds may also induce ACF that have morphologic similarities and differences to ACF induced by genotoxic carcinogens (25) . Based on the data published to date, the assessment of ACF can be used as a screening tool to assess the ability of a compound to induce or alter the development of colonic tumors. However, the assessment of ACF cannot be considered as a definitive endpoint. This is consistent with the observation of Fenoglio-Preiser and Noffsinger in humans that although neoplasia may develop from ACF, many ACF found in human colonic mucosa are likely innocent bystander lesions.
Probably the most important implication of the discovery of ACF as it relates to toxicologic pathology is what we are learning about the biology of the colonic mucosa that is allowing us to begin to differentiate adaptive physiologic alterations from alterations that precede and progress to neoplasia. In the mid 1970s and early 80s, Deschner and colleagues identified focal histologic lesions in the colonic mucosa in experimental animals as the earliest morphologic alteration preceding tumor development (4) . She similarly described alterations in crypt cell proliferation in humans and animals that were focal and highly variable (5) . The focal nature of these lesions was largely forgotten as the concept of the field effect or transitional mucosa was promoted (10, 12) . This field effect concept encompassed many changes in the mucosa adjacent to tumors, which were thought to be precursors to neoplasia. The field effect concept promulgated the notion that preneoplastic changes were diffuse changes that occurred throughout the colon. One change receiving considerable attention was alteration in cell proliferation. Diffuse hyperproliferation was proposed as an important preneoplastic change that could be used to identify individuals at increased risk for the development of colon cancer (15) . This concept of diffuse hyperproliferation as an increased risk for tumor development has been suggested by some, including regulatory agencies, as a relevant endpoint to consider during the safety assessment process (7, 9) . The pitfalls in the use of colonic mucosal cell proliferation in assessing the potential of a compound to alter the development of colonic neoplasia has recently been reviewed (26) . This review points out the importance in distinguishing physiologic adaptive alterations in cell proliferation from those that are associated with progression to neoplasia.
Fenoglio-Preiser and Noffsinger, in their review ( Figs.  1 and 8 ), allude to a shift in the diffuse hyperproliferative paradigm (6) that is beginning to occur. Instead of diffuse hyperproliferation, it is now being proposed that alterations in cell proliferation that are preneoplastic occur in focal areas of the colonic mucosa (e.g., ACF) and not as a diffuse change (14) . This is consistent with the original observation of Deschner that preneoplastic changes are focal in nature. This paradigm shift is supported by recent studies on cell proliferation in humans (8, 12, 13, 16 ) and animal models (1, 3) . It is also supported by the recognition that mucosal alterations associated with the field effect, and once thought to be preneoplastic, may actually be reactive changes in mucosa that are adjacent to tumors (1, 10, 12) . This paradigm shift that is occurring has important implications for toxicologic pathology and the risk assessment of drugs and food additives that may impact the colonic mucosa. There is likely a normal range of cell proliferation in the colonic mucosa that maintains homeostasis (24, 27) . This normal range has not been defined. Diffuse quantitative changes in cell proliferation that fall within the normal range and are not accompanied by alterations in differentiation (e.g., loss of the ability to regulate cell proliferation) are likely physiologic adaptations that do not alter the risk of developing colonic neoplasia (28) . However, quantitative alterations in cell proliferation that are outside the normal range and/or accompanied by a loss of the epithelium's ability to control normal differentiation may increase the risk of neoplastic development. The comparative study of physiologic adaptive responses in the colonic mucosa with alteration that occur in ACF should lead to a better understanding of parameters that differentiate physiologic adaptations in the colonic mucosa from alterations that are associated with an increased risk of developing neoplasia. LAURENCE 
